Letrozole in advanced breast cancer: the PO25 trial.

Breast Cancer Res Treat · 2007 · PMC2001219 · PMID 17333340

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = 0.06so close (0.05 < p ≤ 0.1)

The higher dose of letrozole showed a trend ( P = 0.06) toward superior ORR (19.5%) compared with aminoglutethimide (12.4%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.